170 related articles for article (PubMed ID: 20594415)
1. Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice.
Nakajima T; Tanaka N; Li G; Hu R; Kamijo Y; Hara A; Aoyama T
Redox Rep; 2010; 15(3):123-30. PubMed ID: 20594415
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism.
Nakajima T; Tanaka N; Kanbe H; Hara A; Kamijo Y; Zhang X; Gonzalez FJ; Aoyama T
Mol Pharmacol; 2009 Apr; 75(4):782-92. PubMed ID: 19124612
[TBL] [Abstract][Full Text] [Related]
3. High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes.
Petrescu AD; McIntosh AL; Storey SM; Huang H; Martin GG; Landrock D; Kier AB; Schroeder F
Biochim Biophys Acta; 2013 Aug; 1831(8):1412-25. PubMed ID: 23747828
[TBL] [Abstract][Full Text] [Related]
4. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice.
Peters JM; Aoyama T; Burns AM; Gonzalez FJ
Biochim Biophys Acta; 2003 Jun; 1632(1-3):80-9. PubMed ID: 12782154
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
Guo L; Fang H; Collins J; Fan XH; Dial S; Wong A; Mehta K; Blann E; Shi L; Tong W; Dragan YP
BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S18. PubMed ID: 17118139
[TBL] [Abstract][Full Text] [Related]
6. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Carcinogenesis; 2005 Jan; 26(1):219-27. PubMed ID: 15447978
[TBL] [Abstract][Full Text] [Related]
7. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells.
Wang Y; Wang Y; Yang Q; Yan JT; Zhao C; Cianflone K; Wang DW
Atherosclerosis; 2006 Aug; 187(2):265-73. PubMed ID: 16256120
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice.
Nakajima T; Tanaka N; Sugiyama E; Kamijo Y; Hara A; Hu R; Li G; Li Y; Nakamura K; Gonzalez FJ; Aoyama T
Biochem Pharmacol; 2008 Jul; 76(1):108-19. PubMed ID: 18486101
[TBL] [Abstract][Full Text] [Related]
9. Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.
Kimura R; Takahashi N; Murota K; Yamada Y; Niiya S; Kanzaki N; Murakami Y; Moriyama T; Goto T; Kawada T
Biochem Biophys Res Commun; 2011 Jun; 410(1):1-6. PubMed ID: 21640707
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor α (PPARα) activation advances locomotor activity and feeding daily rhythms in mice.
Gutman R; Barnea M; Haviv L; Chapnik N; Froy O
Int J Obes (Lond); 2012 Aug; 36(8):1131-4. PubMed ID: 22064158
[TBL] [Abstract][Full Text] [Related]
11. Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice.
Tanaka N; Zhang X; Sugiyama E; Kono H; Horiuchi A; Nakajima T; Kanbe H; Tanaka E; Gonzalez FJ; Aoyama T
Biochem Pharmacol; 2010 Nov; 80(10):1601-12. PubMed ID: 20691165
[TBL] [Abstract][Full Text] [Related]
12. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
13. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.
Okiyama W; Tanaka N; Nakajima T; Tanaka E; Kiyosawa K; Gonzalez FJ; Aoyama T
J Hepatol; 2009 Jun; 50(6):1236-46. PubMed ID: 19398233
[TBL] [Abstract][Full Text] [Related]
14. Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a CLOCK-dependent circadian manner.
Oishi K; Koyanagi S; Matsunaga N; Kadota K; Ikeda E; Hayashida S; Kuramoto Y; Shimeno H; Soeda S; Ohdo S
Mol Pharmacol; 2010 Jul; 78(1):135-41. PubMed ID: 20400680
[TBL] [Abstract][Full Text] [Related]
15. [Bezafibrate up-regulate endothelial nitric oxide gene expressions via peroxisome proliferator-activated receptors alpha-dependent and independent pathways in cultured Bovine endothelial cells].
Wang Y; Wang Y; Wang DW
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jun; 34(6):530-6. PubMed ID: 16842672
[TBL] [Abstract][Full Text] [Related]
16. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.
Oishi K; Uchida D; Ishida N
FEBS Lett; 2008 Oct; 582(25-26):3639-42. PubMed ID: 18840432
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome Proliferator-Activated Receptor α Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil.
Shi C; Min L; Yang J; Dai M; Song D; Hua H; Xu G; Gonzalez FJ; Liu A
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):169-174. PubMed ID: 28374976
[TBL] [Abstract][Full Text] [Related]
18. Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver.
Inoue I; Noji S; Awata T; Takahashi K; Nakajima T; Sonoda M; Komoda T; Katayama S
Life Sci; 1998; 63(2):135-44. PubMed ID: 9674948
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of rat liver branched-chain alpha-keto acid dehydrogenase activity by low doses of bezafibrate.
Knapik-Czajka M
Toxicology; 2013 Apr; 306():101-7. PubMed ID: 23485652
[TBL] [Abstract][Full Text] [Related]
20. Activation of peroxisome proliferator-activated receptor-α (PPARα) in proximal intestine improves postprandial lipidemia in obese diabetic KK-Ay mice.
Kimura R; Takahashi N; Goto T; Murota K; Kawada T
Obes Res Clin Pract; 2013; 7(5):e353-60. PubMed ID: 24455763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
